A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1944-446X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS ; volume:35 ; number:1 ; day:28 ; month:10 ; year:2016 ; pages:1-3 ; date:12.2016
Chinese journal of cancer ; 35, Heft 1 (28.10.2016), 1-3, 12.2016
- Urheber
-
Pang, Xiufeng
- Beteiligte Personen und Organisationen
-
Liu, Mingyao
SpringerLink (Online service)
- DOI
-
10.1186/s40880-016-0154-7
- URN
-
urn:nbn:de:1111-201611251255
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pang, Xiufeng
- Liu, Mingyao
- SpringerLink (Online service)
Ähnliche Objekte (12)
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting KRAS mutant cancers: from druggable therapy to drug resistance